Atherosclerosis risk assessment in patients with chronic obstructive pulmonary disease: a case-control study

References

• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. [Updated 2016]. Available from: https://goldcoped.org/. Accessed April 30, 2016.
   Google Scholar
• WHO Fact sheet: the top 10 causes of death dated 24 May 2018 Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 514, 2019.
   Google Scholar
• Roversi S, Roversi P, Spadafora G, Rossi R, Fabbri LM. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest. 2014;44(1):93–102. doi:10.1111/eci.1218124164255
   PubMed Web of Science ®Google Scholar
• Corbi G, Bianco A, Turchiarelli V, et al. Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: focus on Sirtuins. Int J Mol Sci. 2013;14(6):12696–12713. doi:10.3390/ijms14061269623774840
   PubMed Web of Science ®Google Scholar
• Bellocchia M, Masoero M, Ciuffreda A, et al. Predictors of cardiovascular disease in asthma and chronic obstructive pulmonary disease. Multidiscip Respir Med. 2013;8(1):58. doi:10.1186/2049-6958-8-5824004921
   PubMed Web of Science ®Google Scholar
• Acay A, Ulu MS, Ahsen A, et al. Atherogenic index as a predictor of atherosclerosis in subjects with familial Mediterranean fever. Medicina. 2014;50(6):329–333. doi:10.1016/j.medici.2014.11.00925541265
   PubMed Web of Science ®Google Scholar
• Singh M, Pathak MS, Paul A. A study on atherogenic indices of pregnancy induced hypertension patients as compared to normal pregnant women. J Clin Diagn Res. 2015;9(7):Bc05–Bc08. doi:10.7860/JCDR/2015/13505.6241
   PubMedGoogle Scholar
• Millan J, Pinto X, Munoz A, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757–765.19774217
   PubMedGoogle Scholar
• Essiarab F, Taki H, Lebrazi H, Sabri M, Saile R. Usefulness of lipid ratios and atherogenic index of plasma in obese Moroccan women with or without metabolic syndrome. Ethn Dis. 2014;24(2):207–212.24804368
   PubMed Web of Science ®Google Scholar
• D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–753. doi:10.1161/CIRCULATIONAHA.107.69957918212285
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–1482. doi:10.1136/bmj.39609.449676.2518573856
   PubMed Web of Science ®Google Scholar
• Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105(3):310–315. doi:10.1161/hc0302.10257511804985
   PubMed Web of Science ®Google Scholar
• Schols AM, Buurman WA, Staal van Den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51(8):819–824. doi:10.1136/thx.51.8.8198795671
   PubMed Web of Science ®Google Scholar
• Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006;61(1):17–22. doi:10.1136/thx.2005.04199616055618
   PubMed Web of Science ®Google Scholar
• de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27(5):902–907. doi:10.1183/09031936.06.0010960516455829
   PubMed Web of Science ®Google Scholar
• Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med. 2008;19(2):104–108. doi:10.1016/j.ejim.2007.04.02618249305
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–1499. Epub 2014 July 18. doi:10.1016/j.ijsu.2014.07.01325046131
   PubMed Web of Science ®Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.28105324141714
   PubMed Web of Science ®Google Scholar
• International Ethical Guidelines for Epidemiological Studies. Prepared by the Council for International Organizations of Medical Sciences (CIOMS) in Collaboration with the World Health Organization (WHO); 2009 Available from: https://cioms.ch/wp-content/uploads/2017/01/International_Ethical_Guidelines_LR.pdf. Accessed May 13, 2019.
   Google Scholar
• Meenakshisundaram R, Rajendiran C, Thirumalaikolundusubramanian P. Lipid and lipoprotein profiles among middle aged male smokers: a study from southern India. Tob Induc Dis. 2010;8:11. doi:10.1186/1617-9625-8-1120923562
   PubMedGoogle Scholar
• Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J. 2005;26(1):153–161. doi:10.1183/09031936.05.0003450515994402
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.0003480516055882
   PubMed Web of Science ®Google Scholar
• Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968. doi:10.1183/09031936.05.0003520516264058
   PubMed Web of Science ®Google Scholar
• Çakırca G, Çelik MM. Lipid profile and atherogenic indices and their association with platelet indices in familial Mediterranean fever. Turk Kardiyol Dern Ars. 2018;46(3):184–190. doi:10.5543/tkda.2018.9376229664424
   PubMed Web of Science ®Google Scholar
• Tillin T, Hughes AD, Whincup P, et al. Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE–Southall And Brent REvisited). Heart. 2014;100(1):60–67. doi:10.1136/heartjnl-2013-30447424186564
   PubMed Web of Science ®Google Scholar
• Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ. 2010;340:c2442. doi:10.1136/bmj.c29320466793
   PubMed Web of Science ®Google Scholar
• Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med. 2015;36(4):575–591. doi:10.1055/s-0035-155606326238643
   PubMed Web of Science ®Google Scholar
• Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1–16. doi:10.1177/1753465817750524
   Web of Science ®Google Scholar
• Tautu OF, Darabont R, Onciul S, et al. New cardiovascular risk factors and their use for an accurate cardiovascular risk assessment in hypertensive patients. Maedica. 2014;9(2):127–134.25705267
   PubMedGoogle Scholar
• Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008. BMC Pulm Med. 2012;12:26. doi:10.1186/1471-2466-12-2622695054
   PubMed Web of Science ®Google Scholar
• Burtis CA, Ashwood ER, Bruns DE, editors. Tietz Textbook of Clinical Chemistry and Molecular Diagnosis (5th edition). St. Louis, USA: Elsevier ; 2012:2238. ISBN: 978-1-4160-6164-9.
   Google Scholar
• Hancox RJ, Poulton R, Greene JM, et al. Systemic inflammation and lung function in young adults. Thorax. 2007;62(12):1064–1068. doi:10.1136/thx.2006.07687717604302
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med. 2009;179(1):35–40. doi:10.1164/rccm.200804-560OC18931335
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519. doi:10.1161/01.cir.0000056767.69054.b312654609
   PubMed Web of Science ®Google Scholar
• Maclay JD, McAllister DA, Macnee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology. 2007;12(5):634–641. doi:10.1111/j.1440-1843.2007.01136.x17875049
   PubMed Web of Science ®Google Scholar
• Lin GM, Liu K, Colangelo LA, Lakoski SG, Tracy RP, Greenland P. Low-density lipoprotein cholesterol concentrations and association of high-sensitivity C-reactive protein concentrations with incident coronary heart disease in the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2016;183(1):46–52. doi:10.1093/aje/kwv14426597828
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959–1965. doi:10.1056/NEJM20010628344260111430324
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–1565. doi:10.1056/NEJMoa02199312432042
   PubMed Web of Science ®Google Scholar
• Emerging Risk FactorsCollaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–140. doi:10.1016/S0140-6736(09)61717-720031199
   PubMed Web of Science ®Google Scholar
• Riker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369. doi:10.1161/01.cir.0000053730.47739.3c12551853
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–580. doi:10.1136/thx.2003.01958815223864
   PubMed Web of Science ®Google Scholar
• Zhang Y, Bunjhoo H, Xiong W, Xu Y, Yang D. Association between C-reactive protein concentration and chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Int Med Res. 2012;40(5):1629–1635. doi:10.1177/03000605120400050123206444
   PubMed Web of Science ®Google Scholar
• El-Deek SE, Makhlouf HA, Saleem TH, Mandour MA, Mohamed NA. Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease. Med Prin Pract. 2013;22(5):469–474. doi:10.1159/000349934
   PubMed Web of Science ®Google Scholar
• Frohlich M, Sund M, Lowel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J. 2003;24(14):1365–1372. doi:10.1016/s0195-668x(03)00260-412871694
   PubMed Web of Science ®Google Scholar
• Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387–1397. doi:10.1056/NEJMoa03280415070788
   PubMed Web of Science ®Google Scholar
• van Durme YM, Verhamme KM, Aarnoudse AJ, et al. C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(5):375–382. doi:10.1164/rccm.200810-1540OC19096002
   PubMed Web of Science ®Google Scholar
• Dahl M, Vestbo J, Zacho J, Lange P, Tybjaerg-Hansen A, Nordestgaard BG. C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax. 2011;66(3):197–204. doi:10.1136/thx.2009.13119321059738
   PubMed Web of Science ®Google Scholar
• Garg N, Muduli SK, Kapoor A, et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J. 2017;69(4):458–463. doi:10.1016/j.ihj.2017.01.01528822511
   PubMedGoogle Scholar
• Bansal M, Kasliwal RR, Trehan N. Comparative accuracy of different risk scores in assessing cardiovascular risk in Indians: a study in patients with first myocardial infarction. Indian Heart J. 2014;66(6):580–586. doi:10.1016/j.ihj.2014.10.39925634388
   PubMedGoogle Scholar
• Bansal M, Kasliwal RR, Trehan N. Relationship between different cardiovascular risk scores and measures of subclinical atherosclerosis in an Indian population. Indian Heart J. 2015;67(4):332–340. doi:10.1016/j.ihj.2015.04.01726304565
   PubMedGoogle Scholar